Ensign Group (NASDAQ:ENSG) Stock, Quote.Headers.trade-ideas

Ensign Group

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute a majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.

GE Vernova Benefits from Gas Demand

News

Initiation

Markets

Analyst Ratings

Trading Ideas

ENSG

IGIC

MATV

MRUS

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Wall Street

Earnings

Price Target

Ensign Group Analysts Increase Their Forecasts After Q3 Results

Earnings Beats

Large Cap

Mid Cap

Dividends

Health Care

Buybacks

Management

General

Shares of The Cigna Group (NYSE: CI) have gained 25.6% in the past year compared with the industry&#39;s 18.2% growth. The Medical sector and the S&amp;P 500 composite index have rallied 9.3% and 21.2%, respectively, in the same time frame.

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

Ensign Group Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635585064ed0001400105/michael-blum">Wells Fargo analyst Michael Blum </a>initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with an Overweight rating and announced a price target of $385. GE Vernova shares closed at $342.77 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer analyst Michael Phillips initiated coverage on International General Insurance Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGIC#NASDAQ">IGIC</a>) with an Outperform rating and announced a price target of $30. Intl General Insurance shares closed at $24.54 on Wednesday. <a href="https://www.benzinga.com/quote/IGIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Lars Kjellberg initiated coverage on Mativ Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATV#NYSE">MATV</a>) with a Hold rating and announced a price target of $15.5. Mativ shares closed at $12.52 on Wednesday. <a href="https://www.benzinga.com/quote/MATV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Richard Law initiated coverage on Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy rating and announced a price target of $73. Merus shares closed at $42.93 on Wednesday. <a href="https://www.benzinga.com/quote/MRUS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst A.J. Rice initiated coverage on The Ensign Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Buy rating and announced a price target of $175. Ensign Group shares closed at $144.66 on Wednesday. <a href="https://www.benzinga.com/quote/ENSG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-1024x578.png" alt="" class="wp-image-659530" style="width:710px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21132522/image-224.png 1190w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>

In the last three months, 7 analysts have published ratings on Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ensign Group, revealing an average target of $169.14, a high estimate of $175.00, and a low estimate of $165.00. This upward trend is evident, with the current average reflecting a 7.62% increase from the previous average price target of $157.17.
<img src="https://www.benzinga.com/files/images/story/2024/1732194020_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Ensign Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ensign Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ensign Group compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ensign Group's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Ensign Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENSG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ensign Group analyst ratings.</a>
<h2>Discovering Ensign Group: A Closer Look</h2>
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute a majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
<h3>Key Indicators: Ensign Group's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Ensign Group showcased positive performance, achieving a revenue growth rate of 14.99% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ensign Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.25% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ensign Group's ROE excels beyond industry benchmarks, reaching 4.61%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ensign Group's ROA excels beyond industry benchmarks, reaching 1.73%. This signifies efficient management of assets and strong financial health.
Debt Management: Ensign Group's debt-to-equity ratio is below the industry average. With a ratio of 1.15, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Ensign Group Stock: Analyst Perspectives (7 Ratings)

UBS analyst A.J. Rice initiates coverage on Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Buy rating and announces Price Target of $175.

UBS Initiates Coverage On Ensign Group with Buy Rating, Announces Price Target of $175

It acquired the real estate to Marla Vista Assisted Living, an assisted living facility with 40 assisted living beds and 20 memory care beds located in Green Bay, Wisconsin; Marla Vista Manor, a memory care facility consisting of 20 memory care beds located in Green Bay, Wisconsin; Carrington Assisted Living, an assisted living facility with 20 assisted living beds located in Green Bay, Wisconsin; and Carolina Assisted Living, an assisted living facility with 45 assisted living beds located in Appleton, Wisconsin.&nbsp;
Each of these facilities will be operated by affiliates of The Pennant Group, Inc., and subject to long term triple net leases.

Ensign Group Acquires Several Facilities In Wisconsin; No Terms Disclosed

The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign's captive real estate company, and the acquisition is effective as of November 1, 2024.

Ensign Group Acquires The Real Estate And Operations Of Benedictine Living Community Wausau f/k/a Benedictine Manor Of Wausau, An 82-bed Skilled Nursing Facility In Wausau, Wisconsin; No Terms Disclosed

CareTrust REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) announced today that, together with a joint venture partner, it has entered into a binding agreement to acquire a portfolio of skilled nursing facilities for a purchase price of approximately $500 million. The portfolio consists of 31 skilled nursing facilities and a total of 3,290 licensed beds, with 30 of the facilities located in Tennessee and 1 in Alabama. The acquisition is subject to customary closing conditions, and there can be no assurance that the transaction will close in the anticipated timeframe, or at all. The Company anticipates that the transaction will close in the fourth quarter of 2024.
It is anticipated that most of the facilities will be operated by existing CareTrust tenant relationships, including affiliates of The Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>), PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>), and Links Healthcare Group. PACS has agreed to operate 12 of the facilities, Ensign affiliates 9 of the facilities, and Links 7 of the facilities. Three facilities will be master leased to a regional operator that is a new tenant relationship for CareTrust. Three of Ensign's 9 facilities will be acquired by Ensign's real estate subsidiary with the remaining 6 to be included in a new master lease.
The acquisition will be completed through a joint venture arrangement entered into between CareTrust and a large third-party healthcare real estate owner. In connection with the joint venture's acquisition of the portfolio, CareTrust expects to provide a combined common equity and preferred equity investment amount totaling approximately $442 million at an initial contractual yield on its combined preferred and common equity investments in the joint venture of approximately 9.0%.

CTRE

PACS

CareTrust REIT Announces Updated Investments Pipeline Of $700M Including Agreement to Acquire $500M Portfolio In Southeast By Year End

The&nbsp;Ensign Group, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>), the parent company of the EnsignTM&nbsp;group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has agreed to add eight skilled nursing operations in the state of Tennessee and one in Alabama, subject to the completion of certain regulatory approvals and other closing conditions. Six of these operations will be jointly owned by CareTrust REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>, "CareTrust"))) and a large, private joint venture investor and will transition to Ensign affiliated operating companies subject to a new, long-term triple net master leases, and three will be purchased by Standard Bearer Healthcare REIT, Inc., Ensign's captive real estate subsidiary. All nine operations will be operated by Ensign affiliated operating companies. It is anticipated that the transaction will be effective in the next few months.

The Ensign Group Announces Expansion In Tennessee, Agrees To Add Its First Operation In Alabama; Six Of These Operations Will Be Jointly Owned By CareTrust REIT

Ensign Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NYSE">ENSG</a>) short percent of float has fallen 31.44% since its last report. The company recently reported that it has 2.36 million shares sold short, which is 6.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.99 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ensign Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730227512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ensign Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ensign Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ensign Group's peer group average for short interest as a percentage of float is 4.04%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ensign Group's Recent Short Interest

RBC Capital analyst Ben Hendrix maintains Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Outperform and raises the price target from $167 to $172.

RBC Capital Maintains Outperform on Ensign Group, Raises Price Target to $172

The Ensign Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) reported worse-than-expected third-quarter adjusted EPS results and narrowed its FY24 EPS guidance, after the <a href="https://www.benzinga.com/quote/ENSG/earnings">closing bell on Thursday</a>.
Ensign Group reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.38 per share. The company reported quarterly sales of $1.081 billion which beat the analyst consensus estimate of $1.068 billion.
&#8220;Our local leaders continue to consistently drive outstanding clinical and financial performance and we are happy to report another record quarter,&#8221; said Barry Port, Ensign&#8217;s Chief Executive Officer. &#8220;We are particularly impressed with these results when we&#8217;ve added 53 new operations across several markets in our recently acquired bucket.&#8221;
Ensign Group said it sees FY24 adjusted earnings of $5.46 to $5.52 per share, versus analysts' estimates of $5.46 per share. The company expects FY24 revenue of $4.25 billion to $4.26 billion, versus estimates of $4.22 billion.
Ensign shares gained 0.9% to trade at $154.14 on Monday.
These analysts made changes to their price targets on Ensign following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c2a8e2b85e930001ba538c/david-macdonald">Truist Securities analyst David Macdonald</a> maintained Ensign Group with a Hold and raised the price target from $160 to $170.</li>
<li>Stephens &amp; Co. analyst Scott Fidel maintained the stock with an Overweight and raised the price target from $163 to $167.</li>
</ul>
Considering buying ENSG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28111409/image-283-1024x533.png" alt="" class="wp-image-617400" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28111409/image-283-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28111409/image-283-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28111409/image-283-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28111409/image-283.png 1251w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41574887/top-3-industrials-care-stocks-that-plunge-this-month">Top 3 Industrials Care Stocks That Plunge This Month</a></li>
</ul>

Stephens &amp; Co. analyst Scott Fidel maintains Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Overweight and raises the price target from $163 to $167.

Stephens & Co. Maintains Overweight on Ensign Group, Raises Price Target to $167

Truist Securities analyst David Macdonald maintains Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Hold and raises the price target from $160 to $170.

Truist Securities Maintains Hold on Ensign Group, Raises Price Target to $170

Throughout the last three months, 4 analysts have evaluated Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $165.0, with a high estimate of $168.00 and a low estimate of $160.00. Surpassing the previous average price target of $150.75, the current average has increased by 9.45%.
<img src="https://www.benzinga.com/files/images/story/2024/1729879220_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Ensign Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ensign Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ensign Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ensign Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Ensign Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENSG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ensign Group analyst ratings.</a>
<h2>About Ensign Group</h2>
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute a majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
<h3>Ensign Group: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Ensign Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.48% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Ensign Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.85%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.39%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ensign Group's ROA excels beyond industry benchmarks, reaching 1.62%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.18, Ensign Group adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Ensign Group: 4 Analysts Share Their Views

Oppenheimer analyst Michael Wiederhorn maintains Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Outperform and raises the price target from $165 to $168.

Oppenheimer Maintains Outperform on Ensign Group, Raises Price Target to $168

WIIM

Ensign Group shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and narrowed its FY24 EPS guidance.

Guidance

Ensign Group Sees FY24 Adj. EPS $5.46-$5.52 Vs $5.46 Est; Sees FY24 Revenue $4.25B-$4.26B Vs $4.22B Est

Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) reported quarterly earnings of $1.34 per share which missed the analyst consensus estimate of $1.38 by 2.9 percent. The company reported quarterly sales of $1.081 billion which beat the analyst consensus estimate of $1.068 billion by 1.19 percent. This is a 14.90 percent increase over sales of $940.791 million the same period last year.

Earnings Misses

Ensign Group Q3 2024 Adj. EPS $1.34 Misses $1.38 Estimate, Sales $1.081B Beat $1.068B Estimate

Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) has outperformed the market over the past 10 years by 12.64% on an annualized basis producing an average annual return of 23.92%. Currently, Ensign Group has a market capitalization of $8.57 billion. 
Buying $100 In ENSG: If an investor had bought $100 of ENSG stock 10 years ago, it would be worth $895.71 today based on a price of $149.98 for ENSG at the time of writing.
<h3>Ensign Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729719017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $900 Today

Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Ensign Group will report an earnings per share (EPS) of $1.36.
Ensign Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 4.87% increase in the share price the next day.
Here's a look at Ensign Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.30</td>
<td>1.28</td>
<td>1.27</td>
<td>1.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.30</td>
<td>1.28</td>
<td>1.20</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-2.0%</td>
<td>5.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729702907_0.png" alt="eps graph" />
<h3>Performance of Ensign Group Shares</h3>
Shares of Ensign Group were trading at $148.79 as of October 22. Over the last 52-week period, shares are up 55.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Ensign Group</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ensign Group.
Ensign Group has received a total of 3 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $164.0, the consensus suggests a potential 10.22% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Encompass Health, PACS Group and Acadia Healthcare Co, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Encompass Health is favoring an Buy trajectory, with an average 1-year price target of $107.0, suggesting a potential 28.09% downside.</li>
<li>PACS Group is maintaining an Buy status according to analysts, with an average 1-year price target of $43.71, indicating a potential 70.62% downside.</li>
<li>For Acadia Healthcare Co, analysts project an Neutral trajectory, with an average 1-year price target of $86.8, indicating a potential 41.66% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary presents essential metrics for Encompass Health, PACS Group and Acadia Healthcare Co, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensign Group</td>
<td>Outperform</td>
<td>12.48%</td>
<td>$162.65M</td>
<td>4.39%</td>
</tr>
<tr>
<td>Encompass Health</td>
<td>Buy</td>
<td>9.61%</td>
<td>$1.24B</td>
<td>6.33%</td>
</tr>
<tr>
<td>PACS Group</td>
<td>Buy</td>
<td>29.08%</td>
<td>$153.87M</td>
<td>-3.12%</td>
</tr>
<tr>
<td>Acadia Healthcare Co</td>
<td>Neutral</td>
<td>8.85%</td>
<td>$768.16M</td>
<td>2.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ensign Group ranks highest in Revenue Growth among its peers. It is in the middle for Gross Profit. Ensign Group is at the bottom for Return on Equity.
<h3>Unveiling the Story Behind Ensign Group</h3>
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute a majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
<h3>Ensign Group's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Ensign Group's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 12.48%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Ensign Group's net margin excels beyond industry benchmarks, reaching 6.85%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.39%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.62%, the company showcases effective utilization of assets.
Debt Management: Ensign Group's debt-to-equity ratio is below the industry average. With a ratio of 1.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ENSG/earnings">To track all earnings releases for Ensign Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Ensign Group

RBC Capital analyst Ben Hendrix maintains Ensign Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSG#NASDAQ">ENSG</a>) with a Outperform and raises the price target from $133 to $167.

RBC Capital Maintains Outperform on Ensign Group, Raises Price Target to $167

The Ensign Group (ENSG), the parent company of the Ensign group of companies, announced that through subsidiaries of Standard Bearer Healthcare REI...

The Ensign Group announces real state acquisitions

Ensign Group buys assisted living facilities in Wisconsin

2 REIT Winners And 2 REIT Losers From Trump's Reelection

Ensign Group: Expensive Despite Excellent Growth Prospects

Trump Media saw the largest increase in short interest in October

UBS initiated coverage of Ensign Group (ENSG) with a Buy rating and $175 price target Ensign is a proven operator with a strong track record of acq...

Ensign Group initiated with a Buy at UBS

3 REITs With High Dividend Growth Prospects In 2025

Franklin U.S. Small Cap Equity Fund Q3 2024 Commentary

LRT Capital Management November 2024 Investor Update

Universal Health Services: A Healthy Business That Should Translate To Healthy Upside

ACHC

ALGN

AMKR

AMTM

APOS

AZPN

BIRK

CART

CASY

CELH

CGNX

CIGI

CORT

CVLT

DINO

DOCU

ENPH

ENVA

EXPO

FOUR

IIPR

LCID

LINE

LUMN

MDGL

MKTX

NTRA

ODFL

OLLI

PLDGP

RIVN

SIRI

SMCI

SMMT

SWKS

TNET

UPST

VERX

VRNS

ZETA

Press Releases

The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

The Ensign Group Acquires Healthcare Campus in Nebraska

The Ensign Group Announces Appointment of Mark Parkinson to the Board of Directors

The Ensign Group Schedules Third Quarter Earnings Call for Friday, October 25th, 2024

The Ensign Group Reports Third Quarter 2024 Results; Raises Annual Earnings and Revenue Guidance

The Ensign Group Announces Expansion in Tennessee, Agrees to Add Its First Operation in Alabama

CareTrust REIT Announces Updated Investments Pipeline of $700 Million Including Agreement to Acquire $500 Million Portfolio in Southeast by Year End

The Ensign Group Acquires Facilities in Wisconsin

The Ensign Group Increases Presence in Wisconsin

The Ensign Group to Present at the Stephens Annual Investment Conference on November 20, 2024

Comments

Ensign Group

Ensign Group (ENSG) Forecast

Ensign Group (NASDAQ:ENSG) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga